Christopher J. Senner - 02 Jan 2026 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Director
Signature
/s/ Brendan Hannah as attorney-in-fact for Christopher J. Senner
Issuer symbol
QNCX
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
21 Jan 2026, 18:14:06 UTC
Previous filing
06 Jun 2025
Next filing
16 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Senner Christopher J. Director C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO /s/ Brendan Hannah as attorney-in-fact for Christopher J. Senner 21 Jan 2026 0001648367

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Director Stock Option (Right to Buy) Award $0 +21,810 $0.000000 21,810 02 Jan 2026 Common Stock 21,810 $3.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.